Suggestions
Christina M. Hartman
DC-Based External Affairs Professional
Christina M. Hartman is a government affairs professional with extensive experience in policy, advocacy, and leadership roles. She currently serves as the Government Affairs lead at Orchard Therapeutics, a rare disease gene therapy company.4 Prior to this, she held the position of Senior Director of Advocacy at The Assistance Fund, where her annual compensation was $183,578 as of 2024.5
Hartman's career has focused on healthcare policy and rare disease advocacy. She previously worked at bluebird bio, another rare disease gene therapy company, and served as the first head of US Government Relations for the Alliance for Regenerative Medicine (ARM).3 Her experience also includes roles at The Assistance Fund, EveryLife Foundation, and the Pew Charitable Trusts, where she advocated for patient access to care and treatment.3
Hartman holds a Master of Public Health (MPH) with a concentration in epidemiology from the George Washington University School of Public Health.3 She is personally motivated in her work by her experience raising a child with an ultra-rare neurodevelopmental disorder.3
In addition to her professional roles, Hartman has been involved in politics, having run for U.S. Congress in Pennsylvania's former 16th district in 2016 and 2018, and for Pennsylvania auditor general in 2019-2020.12
Hartman currently resides in Bethesda, Maryland, with her husband Matt and their two daughters, Sophie and Charlotte.3
Highlights
Excited to share that I’m starting a new position as Senior Director, Government Affairs at Orchard Therapeutics, a company dedicated to transforming the lives of patients with severe genetic diseases through innovative gene therapy.
I look forward to continuing to serve the rare disease community by continuing to help advance the pipeline of hematopoietic stem cell (HSC) gene therapies designed to address serious diseases. The burden is immense for patients and families like mine - and for society - when current treatment options are limited or do not exist.
My dream is that one day we will have durable genetic therapies to address ultra-rare conditions, like my own daughter Charlotte’s severe neurodevelopmental disorder (NAA10). We still have a long way to go help patients living with and dying from the 95 percent of human diseases that don't have a single FDA-approved product on the market.
Glad to be continuing to work with colleagues and stakeholders in Washington to shape an environment that encourages the discovery, development, licensure - and availability - of durable, potentially curative therapies.
#raredisease #rarediseaseawareness #rarediseaseresearch #genetherapy
Today, bluebird bio celebrates our third FDA approval in less than two years! I’m so proud to be a bluebird and excited for what this news means for sickle cell warriors and their families.
#PersistforPatients #bluebirddays
